Real ChatGPT answer · index seedzxvCKE2KbIMcompleteHealth and wellness · common conditions and symptomscommercial
Find patient-reported outcomes for the newest biologics approved for severe joint inflammation pain, focusing on recovery times and adverse reactions.
Download run
Fan-out diagram
The searches the AI actually ran for this prompt.
SEED QUERY
Find patient-reported outcomes for the newest biologics approved for severe joint inflammation pain, focusing on recovery times and adverse reactions.
1 real search · 1 real-search pass
newest FDA-approved biologics inflammatory arthritis rheumatoid arthritis psoriatic arthritis axial spondyloarthritis 2025 2026 patient reported outcomes pain function adverse eventsGoogle ↗
OBSERVED
Badge and edge weight = share of passes that produced the query. Hover a query for its intent and routing format.
Query classes
Google's semantic query class for every sub-query: what kind of answer each search is after, simulated vs real.
Classifying 1 queries…
Searches and sources
ChatGPT1 real searches · gpt-6
newest FDA-approved biologics inflammatory arthritis rheumatoid arthritis psoriatic arthritis axial spondyloarthritis 2025 2026 patient reported outcomes pain function adverse events Google ↗
- UCB announces U.S. FDA approvals for BIMZELX[®] (bimekizumab-bkzx) for the treatment of psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis · ucb.com
- Control of Inflammation and Sustained Improvements in Patient‐Reported Outcomes in Patients With Psoriatic Arthritis: Bimekizumab Two‐Year Results From Two Phase 3 Studies - Gossec - 2026 - ACR Open Rheumatology · acrjournals.onlinelibrary.wiley.com
- Bristol Myers Squibb - U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis · news.bms.com
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage · jnj.com
Queries
1 queries · click a column to sort